Zika Virus Clinical Trial
Official title:
Phase I Evaluation of Two Zika Viruses for Use in Controlled Human Infection Models (CHIM)
This study will include 4 cohorts of 14 ZIKV and DENV-naïve female and male subjects, 18 - 40 years of age (total: up to 56 subjects). Within each cohort, 10 subjects will receive ZIKV and 4 subjects will receive a placebo on Study Day 0. Cohorts 1 and 2 (Dose = 10^2 PFU) will be enrolled first and will enroll only women. Cohorts 3 and 4 (Dose = 10^2 PFU) will enroll men.
This study is a placebo-controlled, double-blind study in normal healthy adult male and non-pregnant female subjects 18 - 40 years of age, inclusive, recruited from the metropolitan Baltimore/Washington, DC and Burlington, VT areas. The purpose of this study is to evaluate the clinical and virologic response to escalating doses of 2 different ZIKV strains administered subcutaneously in healthy, ZIKV and DENV-naïve, male and non-pregnant, female adult volunteers to identify the most suitable ZIKV strain and dose for use in a ZIKV CHIM. The ZIKV CHIM will then be used to evaluate the protective efficacy of candidate ZIKV vaccines prior to evaluation of these candidates in Phase 2 clinical trials. Both ZIKV strains will be studied at doses of 10^2 PFU. Placebo recipients are included in the study as a control to better assess ZIKV-associated versus non-ZIKV-associated AEs. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Enrolling by invitation |
NCT04182685 -
Evaluation of Medical Conditions Associated With Zika Virus Infection in Managua, Nicaragua
|
||
| Enrolling by invitation |
NCT04398901 -
Neurodevelopmental Outcomes in ZIKV-Exposed Children
|
||
| Completed |
NCT02996890 -
Zika-Vaccine Dose Finding Study Regarding Safety, Immunogenicity and Tolerability (V186-001)
|
Phase 1 | |
| Completed |
NCT03188731 -
ZIKAlliance Pregnant Women Cohort
|
||
| Completed |
NCT03110770 -
VRC 705: A Zika Virus DNA Vaccine in Healthy Adults and Adolescents
|
Phase 2 | |
| Active, not recruiting |
NCT04917861 -
A Study of Zika Vaccine mRNA-1893 in Adult Participants Living in Endemic and Non-Endemic Flavivirus Areas
|
Phase 2 | |
| Completed |
NCT02794181 -
Zika Virus and Related Arbovirus Infections in Deferred Blood Donors (ZVADD)
|
||
| Recruiting |
NCT01099852 -
Cohort of Patients Infected by an Arbovirus
|
||
| Completed |
NCT03611946 -
Evaluation of the Safety and Immunogenicity of the Live Attenuated Zika Vaccine rZIKV/D4Δ30-713 in Flavivirus-naïve Adults
|
Phase 1 | |
| Completed |
NCT04064905 -
Safety, Tolerability, and Immunogenicity of Zika Vaccine mRNA-1893 in Healthy Flavivirus Seropositive and Seronegative Adults
|
Phase 1 | |
| Completed |
NCT03106714 -
Study on the Persistence of Zika Virus (ZIKV) in Body Fluids of Patients With ZIKV Infection in Brazil
|
||
| Completed |
NCT02979938 -
Understanding Excretion and Infectivity of Zika Virus in Semen During and After Infection
|
||
| Recruiting |
NCT03227601 -
Effect of a Posture Adapter for 12 to 24-month Children With Zyka Virus Syndrome
|
N/A | |
| Completed |
NCT03393286 -
ZIKAlliance Children Cohort (ZIKAllianceCH)
|
||
| Completed |
NCT03425149 -
Randomized, Placebo-controlled, Observer-blinded Phase 1 Safety and Immunogenicity Study of Inactivated Zika Virus Vaccine Candidate in Healthy Adults
|
Phase 1 | |
| Completed |
NCT02733796 -
Persistence of Zika Virus in Semen After Acute Infection
|
||
| Completed |
NCT03014089 -
Safety, Tolerability, and Immunogenicity of mRNA-1325 in Healthy Adult Subjects
|
Phase 1 | |
| Completed |
NCT03263195 -
Prospective Cohort Study of HIV and Zika in Infants and Pregnancy
|
||
| Withdrawn |
NCT03204409 -
ZIKAlliance Natural History Study
|